A step towards a universal cancer vaccine

01 Jun 2016

A nanoparticle RNA vaccine that takes advantage of the immune system’s response to viral infection and refocuses it to fight cancer is reported online this week in Nature.

The study shows that the vaccine induces anti-tumour immune responses in mouse tumour models and three patients with advanced melanoma, and possibly represents a step towards a universal vaccine for cancer immunotherapy.

Professor Ugur Sahin, Managing Director (Science and Research) of Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz, and colleagues targeted immune system cells called dendritic cells in mice by using an intravenously administered vaccine made up of RNA-lipoplex nanoparticles — RNA surrounded by a lipid (fatty acid) membrane, similar to a cell membrane.

They find that adjusting the net electrical charge of the nanoparticles to be slightly negative is enough to efficiently target dendritic cells.

The lipoplex protects the RNA from being broken down by the body, and mediates its uptake into dendritic cells and macrophages in the spleen, lymph nodes and bone marrow, where the RNA is then translated into a cancer-specific antigen.

The authors show that this triggers a strong antigen-specific T-cell response and mediates a potent interferon-α (IFNα)-dependent rejection of progressive tumours in several mouse tumour models.

In preliminary results from a human phase I dose escalation trial of the vaccine, the authors show that three melanoma patients treated at a low-dose level experience strong IFNα and antigen-specific T-cell responses.

They conclude that, because almost any protein-based antigen can be encoded by RNA, the nanoparticle vaccine may potentially qualify as a universal vaccine for cancer immunotherapy.

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.